Authors
Loading...
Analysis reveals GPR56 as a significant marker for CD4+ cytotoxic T lymphocytes in autoimmune disorders, suggesting novel therapeutic potential.
Bahabayi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: